COMP <GO>
ARCT vs ENTA // FREE CASH FLOW YIELD
Arcturus Therapeutics Holdings Inc. (NASDAQ) VS. Enanta Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ARCT 3
— ENTA 3
▲ FREE CASH FLOW YIELD LEADER: ENTA
LAST: $12.15 (+0.66%) • MKT CAP: $345.3M
fcf-yield
-21.57%
LAST: $11.15 (-3.46%) • MKT CAP: $324.7M
fcf-yield
-9.91%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARCT VS. ENTA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARCT | ENTA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -21.57% | -9.91% | -11.66 | ENTA | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -46.10% | -3.40% | -42.70 | ENTA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.25 | 0.20 | +1.05 | ARCT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ENTA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 36.6 | +7.89 | ARCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $345.3M | $324.7M | $20.6M | ARCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARCT REV | ENTA REV | ARCT GROSS % | ENTA GROSS % | ARCT FCF | ENTA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $82.0M | $65.3M | — | — | -$74.5M | -$32.2M |
| FY 2024 | $152.3M | $67.6M | — | — | -$60.4M | -$96.7M |
| FY 2023 | $166.8M | $79.2M | — | — | -$18.1M | -$103.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARCT // BETA —
ENTA // BETA —